ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Altering Drp1-Dependent Mitochondrial Fission and Metabolism

被引：0

作者：

Sharma, Priyanka ^{[1
]}

Piya, Sujan ^{[1
,2
]}

Baran, Natalia ^{[3
]}

Zal, Anna ^{[4
]}

Hindley, Christopher J. ^{[5
]}

Dao, Kim-Hien ^{[6
]}

Sims, Martin ^{[5
]}

Zal, Tomasz ^{[3
,4
]}

Ruvolo, Vivian ^{[3
]}

Andreeff, Michael ^{[3
]}

Borthakur, Gautam ^{[3
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Mol Hematol & Therapy, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Div Pathol & Lab Med Clin Trial Operat, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX USA

[5] Astex Pharmaceut, Cambridge, England

[6] Astex Pharmaceut Inc, Pleasanton, CA USA

来源：

关键词：

D O I：

10.1182/blood-2022-167171

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：8789 / 8790

页数：2